We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Renal Cell Carcinoma

Journal Scan / Research · December 22, 2021

NLR, PLR, and SII Index May Predict Oncological Outcomes in Patients With Metastatic RCC Treated With Nivo+Ipi

Journal of Clinical Medicine


Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Clinical Medicine
Utility of Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune Inflammation Index as Prognostic, Predictive Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab and Ipilimumab
J Clin Med 2021 Nov 16;10(22)5325, K Iinuma, T Enomoto, K Kawada, S Fujimoto, T Ishida, K Takagi, S Nagai, H Ito, M Kawase, C Nakai, K Kawase, D Kato, M Takai, K Nakane, K Kameyama, T Koie

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading